{"id":"pegylated-interferon-2","safety":{"commonSideEffects":[{"rate":"70-90","effect":"Flu-like symptoms (fever, chills, fatigue)"},{"rate":"50-70","effect":"Headache"},{"rate":"40-60","effect":"Myalgia"},{"rate":"20-40","effect":"Depression/mood changes"},{"rate":"10-30","effect":"Thrombocytopenia"},{"rate":"10-25","effect":"Neutropenia"},{"rate":"15-30","effect":"Elevated liver enzymes"}]},"_chembl":{"chemblId":"CHEMBL2108506","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Interferon α2 is a cytokine that binds to type I interferon receptors on cell surfaces, triggering JAK-STAT signaling pathways that upregulate antiviral genes and enhance natural killer cell and macrophage activity. Pegylation extends the drug's half-life by reducing renal clearance and proteolytic degradation, allowing for less frequent dosing while maintaining therapeutic levels. This mechanism makes it effective against viral infections and certain malignancies.","oneSentence":"Pegylated Interferon α2 activates innate immune responses by binding to interferon-alpha receptors, enhancing antiviral and anti-proliferative activity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:47:50.684Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C"},{"name":"Chronic hepatitis B"},{"name":"Certain malignancies (melanoma, lymphoma)"}]},"trialDetails":[{"nctId":"NCT04382339","phase":"PHASE1, PHASE2","title":"Sofosbuvir/Pegylated-interferon Plus Ribavirin With HCV Genotype 4","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2015-03","conditions":"Hepatitis C Virus Infection","enrollment":99},{"nctId":"NCT02982837","phase":"PHASE4","title":"To Study the Effect of Adding on Pegylated Interferon (PEG-INF) Therapy for Patients Diagnosed With Chronic Hepatitis B","status":"UNKNOWN","sponsor":"King Abdullah International Medical Research Center","startDate":"2015-03","conditions":"Hepatitis B","enrollment":214},{"nctId":"NCT03090035","phase":"PHASE3","title":"Impact of Interleukin 28B (rs12979860) Genotype on Virological Responses Chronic Hepatitis C Treatment","status":"COMPLETED","sponsor":"Sheikh Zayed Medical College","startDate":"2014-01-01","conditions":"Hepatitis C, Hepatitis C Relapse","enrollment":98}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Unipg"],"phase":"phase_3","status":"active","brandName":"Pegylated Interferon α2","genericName":"Pegylated Interferon α2","companyName":"Sheikh Zayed Medical College","companyId":"sheikh-zayed-medical-college","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pegylated Interferon α2 is a protein-based treatment used to study and treat various conditions, including Hepatitis C, Hepatitis C Relapse, Hepatitis B, and Hepatitis C Virus Infection. It is often used in combination with other treatments, such as Ribavirin or nucleos(t)ide analogues, as part of clinical trials to evaluate its effectiveness in these conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}